文献速递认知障碍与痴呆

阿尔茨海默病中的tau生物标志物:迈向临床实践与试验应用

Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials.
PubMed 文献 · Lancet Neurol · 2022-05-25

本文综述了tau PET、脑脊液和血浆tau生物标志物在阿尔茨海默病中的最新进展,包括第二代tau-PET示踪剂、新型磷酸化tau检测及血液标志物(p-tau181、p-tau217、p-tau231),并讨论了抗tau治疗试验及未来在初级保健等非三级机构验证、头对头比较研究等挑战。

要点

  • 第二代tau-PET示踪剂可检测最早疾病阶段的内侧颞叶亚区tau病理。
  • 血液p-tau181、p-tau217、p-tau231与尸检病理相关,可鉴别阿尔茨海默病与其他痴呆并预测进展。
  • tau-PET成本高、对早期病理敏感性有限及脱靶结合是主要挑战。

核心结论

  • tau-PET和生物体液p-tau标志物的改进已在受控研究环境中实现更早的疾病检测、更准确的诊断方法和预后优化。
  • 神经影像和生物体液tau标志物有潜力通过增强受试者选择、提供靶点结合证据和监测疗效来优化临床试验。

研究设计与样本

  • 本文为综述,未报告系统检索范围。

主要发现

  • 创新性第二代tau-PET示踪剂对阿尔茨海默病tau病理具有高亲和力和选择性,能够检测最早疾病阶段受累的内侧颞叶亚区tau病理。
  • 利用tau-PET发现了新的但常见的tau扩散亚型,提示tau病理在全脑分布上的个体间差异比先前假设的大得多。
  • 脑脊液中新型磷酸化tau(p-tau)检测比既有的tau病理脑脊液标志物更好地反映tau缠结负荷。
  • 血液tau病理生理标志物(即p-tau181、p-tau217和p-tau231)与死后阿尔茨海默病病理相关,可区分阿尔茨海默病与其他类型痴呆,并预测从正常认知和轻度认知障碍向阿尔茨海默病的未来进展。
  • 抗tau治疗领域正在快速发展,有多项正在进行的1期和2期试验,涉及tau翻译后修饰、tau免疫治疗、tau聚集抑制剂以及靶向tau产生和降低细胞内tau水平。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • tau-PET成本高。
  • 对早期阿尔茨海默病病理的检测敏感性部分有限。
  • 存在脱靶示踪剂结合。
  • 需要对生物体液p-tau标志物进行前瞻性验证研究。
  • 检测相关的分析前和分析因素需要进一步改进。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Deposition of tau aggregates is a pathological hallmark of Alzheimer's disease that is closely linked both spatially and temporally to emergence of neurodegeneration and manifestation of clinical symptoms. There is an urgent need for accurate PET, CSF, and plasma biomarkers of tau pathology to improve the diagnostic process in clinical practice and the selection of participants and monitoring of treatment effects in trials. RECENT DEVELOPMENTS: Innovative second-generation tau-PET tracers with high affinity and selectivity to tau pathology in Alzheimer's disease have enabled detection of tau pathology in medial temporal lobe subregions that are affected in the earliest disease stages. Furthermore, novel but common tau spreading subtypes have been discovered using tau-PET, suggesting much greater interindividual differences in the distribution of tau pathology across the brain than previously assumed. In the CSF biomarker field, novel phosphorylated tau (p-tau) assays have been introduced that better reflect tau tangle load than established CSF biomarkers of tau pathology. The advent of cost-effective and accessible blood-based biomarkers for tau pathophysiology (ie, p-tau181, p-tau217, and p-tau231) might transform the Alzheimer's disease field, as these biomarkers correlate with post-mortem Alzheimer's disease pathology, differentiate Alzheimer's disease from other types of dementia, and predict future progression from normal cognition and mild cognitive impairment to Alzheimer's disease. In controlled investigational settings, improvements in tau-PET and biofluid p-tau markers have led to earlier disease detection, more accurate diagnostic methods, and refinement of prognosis. The anti-tau therapy landscape is rapidly evolving, with multiple ongoing phase 1 and 2 trials of post-translational modification of tau, tau immunotherapy, tau aggregation inhibitors, and targeting production of tau and reduction of intracellular tau levels. Neuroimaging and biofluid tau markers hold potential for optimising such clinical trials by augmenting participant selection, providing evidence of target engagement, and monitoring treatment efficacy. WHERE NEXT?: Major challenges to overcome are the high cost of tau-PET, partial sensitivity to detect early-stage Alzheimer's disease pathology, and off-target tracer binding. Prospective validation studies of biofluid p-tau markers are needed, and assay-related preanalytical and analytical factors need further refinement. Future studies should focus on demonstrating the diagnostic and prognostic accuracy of tau biomarkers-blood-based markers in particular-in non-tertiary settings, such as primary care, which is characterised by a diverse population with medical comorbidities. Large-scale head-to-head studies are needed across different stages of Alzheimer's disease to determine which tau biomarker is optimal in various clinical scenarios, such as early diagnosis, differential diagnosis, and prognosis, and for aspects of clinical trial design, such as proving target engagement, optimising participant selection, and refining monitoring of treatment effects.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Ossenkoppele R, van der Kant R, Hansson O, et al. Tau biomarkers in Alzheimer's disease: towards implementation in clinical practice and trials. Lancet Neurol. 2022. PMID: 35643092. doi:10.1016/S1474-4422(22)00168-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。